Personal information

No personal information available

Activities

Employment (1)

Bristol Myers Squibb Co: Princeton, NJ, US

1998-10-07 to present | Scientific Director (Discovery Chemistry)
Employment
Source: Self-asserted source
Upender Velaparthi

Education and qualifications (2)

Indian Institute of Chemical Technology: Hyderabad, Telangana, IN

1986-07 to 2001-06 | Ph.D. (Chemistry)
Qualification
Source: Self-asserted source
Upender Velaparthi

University of Hyderabad: Hyderabad, Telangana, IN

1984 to 1986-06 | M.Sc. (Chemistry)
Qualification
Source: Self-asserted source
Upender Velaparthi

Professional activities (1)

American Chemical Society: Washington, DC, US

1991 to present
Service
Source: Self-asserted source
Upender Velaparthi

Works (21)

Discovery of BMS-986260, a Potent, Selective, and Orally Bioavailable TGFβR1 Inhibitor as an Immuno-oncology Agent

ACS Medicinal Chemistry Letters
2020-02-13 | Journal article
Contributors: Upender Velaparthi; Chetan Padmakar Darne; Jayakumar Warrier; Peiying Liu; Hasibur Rahaman; Karen Augustine-Rauch; Karen Parrish; Zheng Yang; Jesse Swanson; Jennifer Brown et al.
Source: check_circle
Crossref

Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one.

Bioorganic & medicinal chemistry letters
2010-03-27 | Journal article
Source: Self-asserted source
Upender Velaparthi

SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors.

Bioorganic & medicinal chemistry letters
2010-01-21 | Journal article
Source: Self-asserted source
Upender Velaparthi

Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development.

Journal of medicinal chemistry
2009-12-01 | Journal article
Source: Self-asserted source
Upender Velaparthi

Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity.

Journal of medicinal chemistry
2008-09-03 | Journal article
Source: Self-asserted source
Upender Velaparthi

Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.

Bioorganic & medicinal chemistry letters
2008-06-21 | Journal article
Source: Self-asserted source
Upender Velaparthi

2-(1H-Imidazol-4-yl)ethanamine and 2-(1H-pyrazol-1-yl)ethanamine side chain variants of the IGF-1R inhibitor BMS-536924.

Bioorganic & medicinal chemistry letters
2008-01-18 | Journal article
Source: Self-asserted source
Upender Velaparthi

Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.

Bioorganic & medicinal chemistry letters
2007-03-19 | Journal article
Source: Self-asserted source
Upender Velaparthi

Discovery and initial SAR of 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-ones as inhibitors of insulin-like growth factor 1-receptor (IGF-1R).

Bioorganic & medicinal chemistry letters
2007-02-04 | Journal article
Source: Self-asserted source
Upender Velaparthi

Novel 1H-(benzimidazol-2-yl)-1H-pyridin-2-one inhibitors of insulin-like growth factor I (IGF-1R) kinase.

Bioorganic & medicinal chemistry letters
2006-11-17 | Journal article
Source: Self-asserted source
Upender Velaparthi

Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity.

Journal of medicinal chemistry
2005-09-01 | Journal article
Source: Self-asserted source
Upender Velaparthi

Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor.

Cancer research
2005-05-01 | Journal article
Source: Self-asserted source
Upender Velaparthi

Microwave-assisted synthesis of primary amine HX salts from halides and 7 M ammonia in methanol

Tetrahedron Letters
2004-01 | Journal article
Part of ISSN: 0040-4039
Source: Self-asserted source
Upender Velaparthi

Michellamine alkaloids inhibit protein kinase C.

Archives of biochemistry and biophysics
1999-05-01 | Journal article
Source: Self-asserted source
Upender Velaparthi

Antioxidant activity of michellamine alkaloids.

Anticancer research
1999-03-01 | Journal article
Source: Self-asserted source
Upender Velaparthi

Stereospecific Syntheses of Michellamines A and C

Synlett
1997-08 | Journal article
Part of ISSN: 0936-5214
Part of ISSN: 1437-2096
Source: Self-asserted source
Upender Velaparthi

The first stereospecific synthesis of michellamine B

Chemical Communications
1996 | Journal article
Part of ISSN: 1359-7345
Part of ISSN: 1364-548X
Source: Self-asserted source
Upender Velaparthi

The synthesis and biological activity of two analogs of the anti-HIV alkaloid michellamine B

Journal of Heterocyclic Chemistry
1996-07 | Journal article
Part of ISSN: 0022-152X
Part of ISSN: 1943-5193
Source: Self-asserted source
Upender Velaparthi

A practical preparation of functionalized alkylbenzoquinones: synthesis of maesanin and irisquinone

The Journal of Organic Chemistry
1992-05 | Journal article
Part of ISSN: 0022-3263
Part of ISSN: 1520-6904
Source: Self-asserted source
Upender Velaparthi

Total syntheses of (±) cervinomycins A1 and A2

Tetrahedron Letters
1991-09 | Journal article
Part of ISSN: 0040-4039
Source: Self-asserted source
Upender Velaparthi

Stereoconvergent synthesis of a potent mosquito larvicide : (2E,4E,8E,10Z)-N-(2-methyl propyl)-2,4,8,10-dodecatetraeneamide

Tetrahedron
1990-01 | Journal article
Part of ISSN: 0040-4020
Source: Self-asserted source
Upender Velaparthi
grade
Preferred source (of 2)‎

Peer review (2 reviews for 1 publication/grant)

Review activity for ACS medicinal chemistry letters. (2)